Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCUIT: Nivolumab + Radiotherapy in Recurrent Gastric Cancer
NCT03453164Phase 2Completed
- Sponsor
- Fukushima Medical University
- Start
- Mar 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in gastric cancer (GC), sponsored by Fukushima Medical University. Primary endpoint: Disease Control Rate at 6 months. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03453164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453164.